IFW)

1 2 2010 首件E UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 37945-0054

Applicant(s): Angus George DALGLEISH et al.

Confirmation No.: 6757

Appl. No.:

10/624,889

Examiner: Sheela Jitendra Huff

Filing Date:

July 23, 2003

Art Unit: 1642

Title:

HUMAN PROSTATE CELL LINES IN CANCER TREATMENT

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56 and 37 CFR §1.97

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08A is a listing of documents known to applicants in order to comply with applicants' duty of disclosure pursuant to 37 C.F.R. §1.56 and §1.97. A copy of each of the listed documents are being submitted to comply with the provisions of 37 C.F.R. §1.97-1.99.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or is considered to be material to patentability as defined in 37 C.F.R. §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* prior art reference against the claims of the present application.

Applicants believe that the instant Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits under 37 CFR §1.97(b)(3), therefore, no fee is required in connection with its filing.

English translations of the foreign-language documents may not be readily available; however, the absence of such translations does not relieve the PTO from its duty to consider the submitted documents (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that the listed documents be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08A be returned in accordance with M.P.E.P. §609.

Respectfully submitted,

July 12, 2004 Date

John P. Isacson Rég. No. 33,715

HELLER EHRMAN WHITE & MCAULIFFE

1666 K Street, N.W., Suite 300

Washington, D.C. 20006 Phone: (202) 912-2000

Fax: (202) 912-2020 Customer No. 26633

Sheet 1 of 2 PANY ATTY DOCKET NO. SERIAL NO. PTO/SB/08A 37945-0054 10/624,889 APPLICANT INFORMATION DISCLOSURE STATEMENT Angus George DALGLEISH et al. BY APPLICANT **FILING DATE GROUP** July 23, 2004 Date Submitted: July 12, 2004 1642 U.S. PATENT DOCUMENTS CLASS SUBCLASS FILING DATE IF **EXAMINER** DOCUMENT DATE NAME **APPROPRIATE** NUMBER (M/D/Y)INITIAL 6,699,483 DALGLEISH ET AL. 424 A01 3/2/04 277.1 FOREIGN PATENT DOCUMENTS CLASS SUBCLASS TRANSLATION DOCUMENT DATE COUNTRY YES (M/D/Y)NO NUMBER A02 WO93/06867 4/93 WIPO A03 WO97/24132 7/10/97 WIPO WO97/282255 WIPO 8/7/97 A04 OTHER DOCUMENT(S) (Including Author, Title, Date, Pertinent Pages, Etc.) J. Cancer Res. Clin. Oncol. 123: 583-594 (1997) A05 **ABLIN** BERTHON Intl J Oncology, 6(2): 333-343 (1995) A06 Adv Can Res 58: 177-210 (1992) A07 BOON BRENNER ET AL. Journal of Urology, pgs. 1575-1579 (1995) (abstract only) A08 BRIGHT ET AL. Cancer Research (57)(1): 995-1002 (1997) A09 Crit. Rev. in Oncology/Hematology 14:29-39 (1993) A10 CURTI Bio/Technology 12:320 (1994) DERMER A11 DIEDERICHSEN et Oncology Reports 5: 823-826 (1998) A12 DILLMAN et al. Cancer Biotherapy & Radiopharmaceuticals 15(2): 161-168 (2000) A13 A14 DREXLER ET AL. Leukemia and Lymphoma 9:1-25 (1993) **EMBLETON ET** Immunol Ser 23:181-207 (1984) A15 Scand. J. Immunol. 45: 463-470 (1997) A16 ENGEL et al. A17 ESPARAZA et al. J. of Immnology 131(5): 2117-2121 (1983) J. of Immunotherapy 19(5): 364-374 1996) FENTON et al. A18 J. Natl. Cancer Inst. 62(3):585-588 (1979) A19 FOGEL et al. A20 **FRESHNEY** Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., New York, p4 GORELIK ET AL. Journal of Supramolecular Structure 12: 385-402 (1979) (abstract only) A21 Science 278:1041-1042 (1997) A22 GURA Science 278:1064-1068 (1997) A23 HARTWELL ET **EXAMINER** DATE CONSIDERED

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

JUL 1 2 2004 25

| Sheet 1 of 2 | | Tel. | | | | | | |
|--|-----|------------------|--|---|---------------------------------------|------------|---------------------|----------------|
| Sheet 1 of 2 PTO/SB/08A | | | PKO | | ATTY DOCKET NO. SERIAL NO. 10/624,889 | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT | | | | APPLICANT Angus George DALGLEISH et al. | | | | |
| Date Submitted: July 12, 2004 | | | | FILING DATE GROUP 1642 | | | | |
| | | OTHER DOCU | MENT(S) (I | ncluding Auth | nor, Title, Date, Pert | inent Page | s, Etc.) | |
| | A24 | HROUDA et al. | BJU Inter | national 86: 7 | 742-748 (2000) | _ | | |
| | A25 | HSU | NY, pgs. | 764767 (197 | ls and Applications, 3) | Kruse and | Patterson, Eds., Ad | cademic Press, |
| | A26 | JÄGER et al. | Int. J. Car | ncer 71: 142- | 147 (1997) | | | |
| | A27 | JAIN | Sci. Am. 2 | 271:58-65 (19 | 994) | | | |
| | A28 | KAYAGA et al. | Gene The | erapy 6: 1475 | i-1481 (1999) | | | |
| | A29 | KUSUMOTO et al. | Cancer Immunol Immunother 50: 373-381 (2001) | | | | | |
| | A30 | LEHNER et al. | Cancer Immunol Immunother 32: 173-178 (1990) | | | | | |
| | A31 | MARBLE | Cancer W | /eekly Plus, p | 04(2) (1997) | | | |
| | A32 | MORAN | American Medical News 42, 39, 23 (1999) | | | | | |
| | A33 | SCHREIBER et al. | Human G | ene Therapy | 10: 983-993 (1999) |) | | |
| | A34 | TAMURA et al. | Science 2 | 278: 117-120 | (1997) | | | |
| | A35 | TRIEST ET AL. | Clinical C | ancer Res. 4 | (8): 2009-14 (1998) | | | |
| | A36 | VERMORKEN et al. | The Lanc | et 353: 345-3 | 350 (1999) | | | |
| | A37 | VIEWEG ET AL. | | | 1760-1765 (1994) | | | |
| | A38 | VOLPE | Cancer G | enet Cytoger | net 34: 125-134 (198 | 88) | | |
| | A39 | WU ET AL. | Intl J cand | cer, 77(6): 88 | 7-94 (1998) | | | |
| | | | | | | | | |
| | | | | | | , | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| EXAMINER | | | | | DATE CONSIDER | ED | | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.